INO vs. OBIO, LAKE, SKIN, BWAY, KRMD, INFU, SGHT, PDEX, TLSI, and NVRO
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Orchestra BioMed (OBIO), Lakeland Industries (LAKE), Beauty Health (SKIN), BrainsWay (BWAY), KORU Medical Systems (KRMD), InfuSystem (INFU), Sight Sciences (SGHT), Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), and Nevro (NVRO). These companies are all part of the "medical equipment" industry.
Inovio Pharmaceuticals vs.
Orchestra BioMed (NASDAQ:OBIO) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.
Orchestra BioMed has higher revenue and earnings than Inovio Pharmaceuticals.
Orchestra BioMed currently has a consensus target price of $16.25, indicating a potential upside of 207.77%. Inovio Pharmaceuticals has a consensus target price of $12.40, indicating a potential upside of 496.15%. Given Inovio Pharmaceuticals' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Orchestra BioMed.
In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Orchestra BioMed. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 0 mentions for Orchestra BioMed. Inovio Pharmaceuticals' average media sentiment score of 0.14 beat Orchestra BioMed's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.
Inovio Pharmaceuticals received 708 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 71.15% of users gave Inovio Pharmaceuticals an outperform vote.
Orchestra BioMed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Inovio Pharmaceuticals has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,179.33%. Orchestra BioMed's return on equity of -107.04% beat Inovio Pharmaceuticals' return on equity.
53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by company insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Orchestra BioMed beats Inovio Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INO) was last updated on 1/21/2025 by MarketBeat.com Staff
